Cargando…

Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern

INTRODUCTION: SARS-CoV-2 vaccination is the leading strategy to prevent severe courses after SARS-CoV-2 infection. In our study, we analyzed humoral and cellular immune responses in detail to three consecutive homologous or heterologous SARS-CoV-2 vaccinations and breakthrough infections. METHODS: P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruhl, Louisa, Kühne, Jenny F., Beushausen, Kerstin, Keil, Jana, Christoph, Stella, Sauer, Jasper, Falk, Christine S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073596/ https://www.ncbi.nlm.nih.gov/pubmed/37033958 http://dx.doi.org/10.3389/fimmu.2023.1120010

Ejemplares similares

Variances in Humoral Responses to Different Spike Protein Domains After SARS-CoV-2 Vaccination in Lung and Heart Transplant Recipients
por: Sauer, J., et al.
Publicado: (2022)

Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks
por: Ruhl, Louisa, et al.
Publicado: (2021)

Composition of ex vivo perfusion solutions and kinetics define differential cytokine/chemokine secretion in a porcine cardiac arrest model of lung preservation
por: Radomsky, Lena, et al.
Publicado: (2023)

(348) Longitudinal Dynamics of SARS-CoV-2 Spike-Specific Antibody Responses in Patients on Waiting List and after Lung Transplantation
por: Hübner, M., et al.
Publicado: (2023)

Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses
por: Buscot, Matthieu, et al.
Publicado: (2023)

Cellular and Humoral Immune Responses after Breakthrough Infection in Patients Undergoing Hemodialysis
por: Toda, Masataro, et al.
Publicado: (2023)

CD14(high)CD16(+) monocytes are the main producers of Interleukin-10 following clinical heart transplantation
por: Ludwig, Kristina, et al.
Publicado: (2023)

SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection
por: Pušnik, Jernej, et al.
Publicado: (2023)

Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
por: Zhang, Yuwei, et al.
Publicado: (2023)

Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
por: McKenzie, Duncan R., et al.
Publicado: (2022)

Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19
por: Lee, Chan Mi, et al.
Publicado: (2023)

Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
por: McNamara, Ryan P., et al.
Publicado: (2023)

Pulmonary immune profiling of SIDS: impaired immune maturation and age-related cytokine imbalance
por: Qu, Dong, et al.
Publicado: (2022)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium
por: Calcoen, Bas, et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation-a prospective six month follow-up
por: Kirchner, Theresa, et al.
Publicado: (2022)

Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2022)

Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
por: Maaske, Jill, et al.
Publicado: (2023)

Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
por: Hyun, Hakjun, et al.
Publicado: (2023)

Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab
por: Hall, Victoria G, et al.
Publicado: (2023)

Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19
por: Kirchner, Theresa, et al.
Publicado: (2022)

Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance
por: Chinnadurai, Rajkumar, et al.
Publicado: (2022)

Kinetics of cellular and humoral responses to third COVID-19 vaccine in heart transplant recipients: Correspondence
por: Sokaromdee, Pathum, et al.
Publicado: (2022)

Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
por: Gallais, Floriane, et al.
Publicado: (2022)

Third booster vaccination and stopping the Omicron, a new variant of concern
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Third booster vaccination and stopping the Omicron, a new variant of concern
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Concerning Third Molars
por: Brackett, C. A.
Publicado: (1891)

Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico
por: Galán-Huerta, Kame A., et al.
Publicado: (2022)

A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse
por: Westhoff, Timm H., et al.
Publicado: (2021)

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
por: Lasagna, A., et al.
Publicado: (2022)

Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients
por: Wand, Ori, et al.
Publicado: (2022)

Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees
por: Yu, Pei, et al.
Publicado: (2023)

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
por: Obeid, Michel, et al.
Publicado: (2022)

Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern
por: Yadav, Pragya D., et al.
Publicado: (2022)

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
por: Felten, Renaud, et al.
Publicado: (2022)

Donor NK and T Cells in the Periphery of Lung Transplant Recipients Contain High Frequencies of Killer Cell Immunoglobulin-Like Receptor-Positive Subsets
por: Hitz, Anna-Maria, et al.
Publicado: (2021)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
por: Peled, Yael, et al.
Publicado: (2022)

Breakthrough Invasive Candidiasis in Children
por: Dong, Sara, et al.
Publicado: (2017)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - Implications for the omicron variant: Correspondence
por: Peled, Yael, et al.
Publicado: (2022)

Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination
por: Caniels, Tom G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bqgjb1luhv4i40cgp4h5kh7jhg